MONOPAR
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds. Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conducting Hu-ATN-658’s early development, including a Phase I clinical trial. In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.
MONOPAR
Social Links:
Industry:
Biopharma Biotechnology Developer Tools Health Care Therapeutics
Founded:
2014-01-01
Address:
Wilmette, Illinois, United States
Country:
United States
Website Url:
http://www.monopartx.com
Total Employee:
1+
Status:
Active
Contact:
(847) 388-0349
Email Addresses:
[email protected]
Total Funding:
2.11 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Amazon Virginia Region Name.com DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.monopartx.com
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Monopar"
Monopar Therapeutics Inc. (MNPR)
7 rows · Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic …See details»
Profile :: Monopar Therapeutics Inc. (MNPR)
Business Description. Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage …See details»
Overview :: Monopar Therapeutics Inc. (MNPR)
Monopar Therapeutics' mission is to acquire, develop and commercialize promising oncology product candidates that address the unmet medical needs of cancer patients.See details»
Our Team :: Monopar Therapeutics Inc. (MNPR)
Dr. Robinson, in 2010, co-founded and was CEO of Tactic Pharma. He helped lead Tactic through a successful sale of its lead compound. His passion is leveraging his interests in medicine, …See details»
Monopar and NorthStar Amend & Extend Collaboration
Jun 11, 2024 · Under terms of the revised collaboration, the Companies entered into a long-term, non-exclusive master supply agreement for NorthStar to provide Monopar with the powerful …See details»
Monopar Therapeutics - Overview, News & Similar companies
Monopar Therapeutics contact info: Phone number: (847) 388-0349 Website: www.monopartx.com What does Monopar Therapeutics do? Monopar's mission is to develop …See details»
Monopar Therapeutics Inc. | LinkedIn
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.See details»
Monopar Therapeutics Reports Third Quarter 2024 Financial …
WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on …See details»
MNPR Stock Price Quote | Morningstar
Nov 15, 2024 · See the latest Monopar Therapeutics Inc stock price (MNPR:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
Monopar Presents Encouraging Human Clinical Dosimetry Data
Oct 22, 2024 · MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for …See details»
2024-10-22 | Monopar Presents Encouraging Human Clinical
Oct 22, 2024 · MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for …See details»
Monopar Presents Encouraging Human Clinical Dosimetry
Oct 22, 2024 · MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for …See details»
Monopar Announces Agreement with Alexion, AstraZeneca Rare …
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments …See details»
Publications :: Monopar Therapeutics Inc. (MNPR)
Toggle navigation. Pipeline Pipeline. Pipeline Chart; uPAR-targeted radiopharmaceuticals; MNPR-101. OverviewSee details»
Monopar Therapeutics Inc. (MNPR) - Stock Analysis
Nov 21, 2024 · Get a real-time Monopar Therapeutics Inc. (MNPR) stock price quote with breaking news, financials, statistics, charts and more.See details»
Monopar Presents Data Showing Tumor Reduction Benefit of …
Nov 1, 2023 · Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/Camsirubicin/mnpr-201-001-clinical-trial. Clinical Trial …See details»
2. Principal Place of Business and Contact Information
Oil & Gas Other Energy 5. Issuer Size Revenue Range Aggregate Net Asset Value Range No Revenues No Aggregate Net Asset Value $1 - $1,000,000 $1 - $5,000,000See details»
MNPR-101 - Monopar Therapeutics Inc.
General 1. Mahmood, et al. Bone Res. 2020.https://www.ncbi.nlm.nih.gov/pubmed/32337090 2. de Geus, et al.Biomark Insights. 2017.https://www.ncbi.nlm.nih.gov/pubmed ...See details»
Monopar Therapeutics LLC | Insights
Jul 25, 2023 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Pipeline Chart :: Monopar Therapeutics Inc. (MNPR)
Phase 3 in progress. Phase 3 - Primary Endpoint Met Phase 2 - MOA Inconclusive, Endpoints Not MetSee details»